Pay in 4 interest-free payments of $6.41 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
doi: 10.1016/S0378-4290(98)00131-2 CrossRef Full Text | Google Scholar Ross, C., Saggar, S., Yeates, G., Dando, J., and Shepherd, G
Cardiovascular Outcomes# EXSCEL Trial (Exenatide)# The EXSCEL trial (Holman et al., NEJM 2017) enrolled 14,752 patients with type 2 diabetes (73.1% with prior cardiovascular disease) and followed them for a median of 3.2 years: Primary MACE endpoint : HR 0.91 (95% CI 0.83-1.00), p=0.06 for superiority Met non-inferiority but narrowly missed superiority (p=0.06) All-cause mortality was reduced by 14% (HR 0.86, p=0.016) in a secondary analysis EXSCEL confirmed cardiovascular safety but did not prove cardiovascular benefit -- a critical distinction
Cardio & Gut Health*
This is when the body becomes less responsive to the peptide over time
US$ 21.24
US$ 22.83
US$ 24.62
US$ 28.34
US$ 26.20
US$ 27.00
US$ 24.17
US$ 27.14
